Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a cash flow conversion efficiency ratio of 0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-349.69K) by net assets ($-2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Lakewood-Amedex Biotherapeutics Inc. Com free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see how much is Lakewood-Amedex Biotherapeutics Inc. Com worth for the company's overall valuation and market capitalisation.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lakewood-Amedex Biotherapeutics Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Odyssean Investment Trust PLC
LSE:OIT
|
0.000x |
|
Mustang Bio Inc
NASDAQ:MBIO
|
-0.267x |
|
New Plus Knitting Public Company Limited
BK:NPK
|
-0.003x |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
0.039x |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
-0.126x |
|
Bio-Gene Technology Ltd
AU:BGT
|
-0.811x |
|
Adherium Ltd
AU:ADR
|
9.437x |
|
Sabre Resources Ltd
AU:SBR
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025. View latest Lakewood-Amedex Biotherapeutics Inc. Com stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.96 Million | $-1.94 Million | 0.990x | +107.08% |
| 2024-12-31 | $409.61K | $-5.72 Million | -13.973x | -834.43% |
| 2023-12-31 | $4.56 Million | $-6.82 Million | -1.495x | -- |
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more